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CASE PRESENTATION
A 42-year-woman with a history of juvenile-onset diabetes mellitus was
referred to University Hospitals of Cleveland for pancreas transplanta-
tion. Diabetes was first diagnosed at age 15, and insulin therapy was begun
at that time. At the time of her referral, her serum creatinine concentra-
tion was 1.4 mg/dl and the creatinine clearance 80 ml/min. Protein
excretion was 1.2 g/24 hrs. Diabetic retinopathy, discovered four years
earlier, had been treated with laser surgery. A cadaveric pancreatic
transplant was performed using pancreaticoduodenocystotomy. The pa-
tient’s postoperative course was complicated by a peripancreatic abscess
that required surgical drainage on two occasions. The patient was eugly-
cemic and insulin-independent until one month following surgery, when
overt hyperglycemia and a relative decrease in urinary amylase excretion
prompted a 10-day course of treatment with OKT3 for presumed acute
allograft rejection. Her blood sugar level returned to the normal range;
five months later, however, a second rejection episode did not respond to
treatment with OKT3. The patient’s pancreatic allograft was surgically
removed and insulin therapy was renewed.
During the subsequent 18 months, the patient developed peripheral
vascular disease requiring a right transmetatarsal amputation; this was
followed by a right, below-the-knee amputation. During this interval, the
patient’s renal function gradually deteriorated, in part because of two
episodes of contrast-medium-induced nephropathy following aortography.
She developed end-stage renal disease requiring initiation of maintenance
hemodialysis.
Two years following the initial pancreatic transplant, the patient re-
ceived simultaneous kidney and pancreas transplants from one cadaveric
donor. Maintenance immunosuppression consisted of cyclosporine, pred-
nisone, and azathioprine. One month following transplantation, the
patient was treated with OKT3 for acute renal allograft rejection. There-
after, she maintained excellent renal allograft function. Glycohemoglobin
levels, which had ranged between 8.5% and 9.3% during the six months
prior to transplantation, decreased to 4.3% within two months of trans-
plantation. Visual acuity measured within two months after the transplant
procedure was 20/300 OD and 20/200 OS.
In the seven years following combined kidney-pancreas transplantation,
the patient was readmitted to the hospital on 12 occasions. Three separate
hospital admissions were prompted by gross hematuria. Cystoscopic
evaluation revealed only acute and chronic inflammation of the bladder
mucosa and duodenal cuff. Recurrent hematuria prompted enteric con-
version of the pancreatic allograft via a pancreaticojejunostomy approxi-
mately six years following transplanation. Two years later, the patient
developed gangrene of the left foot, which required a left Syme’s
amputation. Five years following kidney-pancreas transplantation, the
patient published an autobiography detailing how the transplant had
improved her quality of life. At last followup, her serum creatinine
concentration was 1.1 mg/dl; glycohemoglobin was 3.8%. Visual acuity was
20/30 OD and 20/25 OS.
DISCUSSION
DR. DONALD E. HRICIK (Professor and Director, Division of
Nephrology, Department of Medicine, Case Western Reserve Univer-
sity, Cleveland, Ohio, USA): Transplantation of beta cells, either as
part of a vascularized pancreatic allograft or as dispersed islets,
remains the only therapy capable of establishing an insulin-
independent, euglycemic state in patients with diabetes mellitus.
Although vascularized pancreas transplantation has been more
successful than islet cell transplantation to date, it requires a
major operation. The patient presented here illustrates many of
the surgical complications of pancreatic and combined kidney-
pancreas transplantation in an individual who also has experi-
enced the major benefits of the operation: insulin independence
and an improved quality of life. Despite continued controversy
about the benefits and risks of the procedure [1, 2], data from the
International Pancreas Transplant Registry indicate that the
number of pancreas transplants steadily increased between 1988
and 1996 (Fig. 1). During that time interval, more than two-thirds
of the pancreatic transplants were performed as simultaneous
kidney-pancreas transplants; the remainder were equally divided
between pancreatic transplants performed after prior kidney
transplants, and pancreatic transplants performed prior to the
development of end-stage renal disease. In this discussion, I will
focus on the outcomes, benefits and risks of combined kidney-
pancreas transplantation in patients with type-I diabetes mellitus
and end-stage renal disease.
Surgical issues
Technical considerations. Since the first pancreas transplant in
1966 [3], considerable debate has focused on how the operation
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should be performed. Currently, the majority of pancreatic trans-
plants in the United States are performed with a simultaneous
kidney transplant from the same cadaveric donor using the whole
pancreas and a portion of the donor duodenum anastomosed via
a pancreaticoduodenocystostomy to achieve exocrine drainage via
the bladder [4]. Venous drainage of the pancreas usually is
established via the iliac veins into the systemic circulation. As
conceived by Nghiem and Corry [5], the main advantage of
bladder drainage is that it allows monitoring of the urinary
concentration of amylase and other urinary enzymes, and thus
permits detection of acute rejection of the pancreas before the
development of overt hyperglycemia. Unfortunately, bladder
drainage of the exocrine pancreas also produces several urologic
and metabolic complications that I will discuss later. Moreover,
drainage of pancreatic venous effluent into the systemic venous
circulation eliminates the first-pass metabolism of insulin nor-
mally delivered to the liver via the portal circulation and produces
relative hyperinsulinism. Some centers espouse the use of enteric
drainage of the exocrine pancreas and/or venous drainage into the
portal circulation [6, 7]. Hughes et al reported improved lipid
profiles in pancreatic transplant recipients after portal venous
drainage compared to profiles in patients managed with systemic
venous drainage [8]. It remains to be determined, however,
whether this modification in surgical technique influences the
survival of either the allograft or the patient.
Transplantation of a segment of the pancreas (body and tail)
continues to be performed at some centers and is the technique
employed in rarely performed living-related pancreatic trans-
plants [9]. In segmental pancreatic transplantation, various ap-
proaches for handling exocrine pancreatic secretions have in-
cluded ductocystostomy, ligation of the pancreatic duct,
anastomosis to the recipient ureter, or obliteration of the ductal
system by injection of synthetic polymers. Among the majority of
centers performing transplantation of the whole pancreas via
pancreaticoduodenocystostomy, arguments persist about the ap-
propriate size of the duodenal cuff [10] and whether to place the
pancreatic allograft in the intra- or extraperitoneal space.
Complications of bladder drainage. Complications of pancreatic
transplantation related to bladder drainage constitute a major
cause of morbidity and occur in more than 40% of kidney-
pancreas transplant recipients [11]. Table 1 lists the major meta-
bolic and urologic complications of pancreaticoduodenocystos-
tomy. The most common metabolic complication, metabolic
acidosis, occurs in 75% to 100% of bladder-drained patients [7,
12, 13], and results from urinary loss of bicarbonate contained in
the exocrine secretions of the pancreatic allograft. Acute and
chronic volume depletion and a relatively high incidence of
calcium-containing bladder stones undoubtedly are related di-
rectly to the loss of sodium and bicarbonate that typically result in
a persistently alkaline urine. For unclear reasons, the need for
bicarbonate replacement tends to diminish with time after trans-
plantation in most patients.
Wound infections, reported in 26% to 61% of kidney-pancreas
graft recipients [12, 14, 15], represent a major cause of postoper-
ative morbidity. The high incidence of wound infection presum-
ably is related to loculated pancreatic surface secretions, but
prolonged bladder catheterization, underlying diabetic bladder
dysfunction [16], and reflux of urine into the pancreatic allograft
all play a role. Wound infection rates appear to be lower when the
pancreatic allograft is placed within the peritoneal cavity [9, 15].
Secretion of pancreatic enzymes into the lower urinary tract can
cause chemical cystitis or urethritis that sometimes results in
severe dysuria or gross hematuria.
These complications occasionally warrant surgical conversion
of exocrine pancreatic drainage from the bladder to the intestine
via either a jejunostomy or a Roux limb. Stephanian et al reported
the need for cystoenteric conversion in 6 of 265 consecutive
patients (6%) [17]. The most common indications for conversion
were intractable metabolic acidosis and chemical urethritis. Sindhi
et al reviewed their experience with enteric conversion for meta-
bolic (65%) or urologic (35%) complications and concluded that
the procedure is safe and has little peri-operative risk [18].
Nevertheless, complications of bladder drainage and the occa-
sional need for enteric conversion clearly increase rates of hospi-
tal readmission, length of hospital stay, and the cost of kidney-
pancreas transplantation when compared with kidney
transplantation alone [14].
Fig. 1. Pancreas transplants performed in the United States between
1988 and 1995 including total number (f), number of combined renal-
pancreatic transplants (M), and number of pancreas-only transplants
(o).
Table 1. Complications of pancreas transplantation using bladder
drainage via pancreaticoduodenocystostomy
Metabolic
Acidosis (bicarbonate depletion)
Sodium depletion
Calcium bladder stones
Surgical/urologic
Wound infection
Urinary tract infection
Chemical cystitis/urethritis
Hematuria
Dysuria
Reflux pancreatitis
Pancreatic fistulae
Bladder anastomotic leaks
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Outcomes
Pancreatic outcomes.The technical success of whole-organ or
segmental pancreatic transplantation is limited by early allograft
thrombosis, which occurs in 3% to 12% of patients [12, 15, 19].
These early technical failures account, in part, for the observation
that one-year pancreatic allograft survival rates are lower than
survival rates for the simultaneously transplanted kidney [20] (Fig.
2). Registry data suggest that pancreatic allograft survival in
patients undergoing combined kidney-pancreas transplantation is
superior to that of patients undergoing pancreas transplantation
after kidney transplantation (PAK) or pancreatic transplantation
alone (PTA) (Fig. 3). This phenomenon might be explained by a
loss of isolated pancreatic allografts resulting from difficulties in
diagnosing early pancreatic rejection. It is also possible that the
isolated pancreatic allograft is more immunogenic than is a renal
or combined renal-pancreatic allograft. It is interesting that HLA
matching has improved pancreatic allograft survival after PAK
and PTA, but not after combined kidney-pancreas transplantation
[21].
Alternatively, a simultaneously transplanted kidney might
somehow protect the pancreas from acute allograft rejection. The
entrapment hypothesis put forth by Kyriakides et al [22] and
Severyn et al [23] suggests that immunocompetent cells are
diverted to the renal allograft and away from the pancreatic
allograft on the basis of higher blood flow rates to the kidney.
According to the dilution hypothesis, the presence of two allo-
grafts dilutes a fixed number of effector cells generated during
acute rejection, thus minimizing rejection of the pancreas after
combined kidney-pancreas transplantation [23]. Unfortunately,
animal models have not provided consistent data to support either
of these hypotheses. In rats, pancreatic allografts are preferen-
tially rejected after kidney-pancreas transplantation [24]. In pigs,
a renal allograft appears to protect a simultaneous pancreatic
allograft from rejection [25].
In many centers, the most common cause of failure of pancre-
atic allografting beyond the immediate posttransplant period is
death with a functioning graft [26, 27]. Douzdjian and coworkers
found that cardiovascular disease was responsible for 60% of
deaths in 61 kidney-pancreas recipients [27]. This is all the more
remarkable considering that diabetic patients usually are selected
for combined kidney-pancreas transplantation based on the ab-
sence of pre-existing cardiovascular disease [12]. Future efforts at
minimizing cardiovascular disease after transplantation are
needed to improve both patient and allograft survival.
Patterns of rejection. Investigators in this field generally ac-
knowledge that pancreatic rejection manifested by overt hyper-
glycemia is usually far advanced and irreversible. A number of
laboratory tests have been used as measures of early pancreatic
rejection (Table 2) [28–34]; however, none has been sufficiently
sensitive or specific to be a reliable, noninvasive method of
diagnosing acute rejection. In patients whose transplant has
involved bladder drainage of the exocrine pancreas, a relative
decrease in urinary amylase secretion remains the best marker of
pancreatic rejection. Benedetti and colleagues studied hypoamy-
lasuria as a predictor of biopsy-proved pancreatic rejection and
found its sensitivity to be 100% and specificity to be 30% [28].
Others have argued that the benefit of measuring urinary amylase
is limited by large intra- and intersubject variability that might be
related to hormonal influences on exocrine pancreatic function
[29]. Although pancreatic histopathology is the gold standard for
diagnosing rejection, pancreatic biopsies are not widely per-
formed because of the perceived risk of complications such as
Fig. 3. Pancreatic allograft survival in bladder-drained recipients of
combined kidney-pancreas transplants (SPK), pancreatic allografts after
prior renal transplantation (PAK), and pancreatic allografts prior to the
development of end-stage renal disease (PTA) in patients between 1987
and 1993 in the U.S. (Adapted with permission from Ref. 20.)
Table 2. Diagnostic test for pancreatic allograft rejection
Noninvasive
Decreased urinary amylase
Decreased urine pH
Increased serum trypsin or trypsinogen
Increased plasma levels of pancreatic secretory trypsin inhibitor
Hyperamylasemia
Hyperglycemia
Decreased rate of glucose disappearance during intravenous glucose
tolerance testing
Decreased insulin release after intravenous glucose or glucagon
Invasive
Fine-needle aspiration
Biopsy
Percutaneous
Cystoscopic
Fig. 2. Patient (Pt), kidney (Kx), and pancreas (Px) survival in recipients
with kidney-pancreas transplants between 1987 and 1993 in the U.S.
(Adapted with permission from Ref. 20.)
Nephrology Forum: Kidney-pancreas transplantation 1093
bleeding and allograft pancreatitis. In fact, centers with large
experiences (using either cystoscopic or percutaneous pancreatic
biopsies) generally report few complications. For example, Klas-
sen et al performed 40 consecutive biopsies in 19 patients and
reported only one episode of intrabdominal bleeding and no
changes in serum amylase or lipase that might suggest pancreatitis
[35].
In recipients of combined kidney-pancreas transplants, acute
rejection involving both allografts is readily recognized by an
increased serum creatinine concentration, a surrogate marker for
otherwise unrecognized pancreatic rejection. Expeditious treat-
ment of such episodes undoubtedly contributes to improved
pancreatic survival in recipients of combined transplants, as
compared with recipients of isolated pancreatic transplants. How-
ever, results from centers using either percutaneous or cystoscopic
pancreatic biopsies to diagnose acute pancreatic allograft rejec-
tion have clearly shown that pancreatic and renal allograft rejec-
tion can occur independently. Klassen et al performed pancreatic
biopsies that were clinically indicated based either on a twofold
increase in serum amylase or a sustained 50% decrease in urine
amylase; acute rejection of the pancreas was found in 27% of the
biopsies in the absence of histologic or clinical evidence of renal
allograft rejection [35]. The same group recently reported a
relatively high incidence of late pancreatic rejection episodes
(defined as occurring more than one year post transplant),
especially in patients receiving low doses of immunosuppressants
[36]. Other centers performing serial “protocol” biopsies have
reported as much as an 18% incidence of occult acute rejection of
the pancreas [37, 38]. Although short-term pancreatic allograft
survival is inferior to the survival of simultaneously transplanted
renal allografts, recent data from single centers suggest that
pancreatic allograft half-life exceeds that of the renal allografts
(Fig. 4) [39, 40]. These observations suggest that, in contrast to
renal allografts, pancreatic allografts are relatively resistant to
chronic rejection. Patients who have returned to chronic dialysis
as a consequence of chronic renal allograft rejection but who have
retained functioning pancreatic allografts are not uncommon.
Management of immunosuppression represents a unique chal-
lenge in such patients because of the concomitant effects of
uremia on the immune system.
Renal outcomes. Although a simultaneous kidney transplant
might protect the pancreas from acute rejection, most [14, 15,
41–43] but not all [44] investigators agree that acute renal
allograft rejection rates are higher after combined kidney-pan-
creas transplantation than in diabetic or nondiabetic control
groups who receive kidney transplants alone. The notion that
transplanted pancreatic tissue increases the immunogenicity of a
simultaneous renal allograft is supported by observations from
Carroll et al, who reported a 100% rate of renal rejection in 9
patients who received combined kidney and islet cell transplants
[45]. Animal models have not been helpful in explaining this
phenomenon. For example, renal allograft rejection rates in pigs
are no different after kidney-pancreas transplantation than after
kidney transplantation alone [25].
Some centers have reported lower rates of renal allograft [46,
47] or patient [48, 49] survival after combined kidney-pancreas
transplantation. However, registry data indicate that short-term
renal allograft survival in combined kidney-pancreas transplant
recipients is either comparable [50] or superior [51] to that in
diabetics receiving a kidney alone (Fig. 5). Thus, somewhat
surprisingly, higher rates of acute renal rejection after kidney-
pancreas transplantation do not seem to affect at least short-term
renal survival rates.
Studies of renal function, as measured by serum creatinine
concentrations or other estimates of glomerular filtration rate,
generally have indicated no differences between diabetic patients
receiving a combined renal-pancreatic transplant or a kidney
alone [52–55]. However, these studies have been limited by
inclusion of either small numbers of patients or selected patients
followed for relatively short periods. Few studies to date have
Fig. 4. Patient (f), pancreatic allograft (l), and renal allograft (*)
half-lives as determined by linear regression. (Reprinted with permission
from Ref. 40.)
Fig. 5. Renal allograft survival in patients who received cadaveric kid-
neys between 1987 and 1993 in the U.S. Kidney-pancreas recipients (u);
kidney-alone recipients with end-stage renal disease secondary to glomer-
ulonephritis (E); kidney-alone recipients with end-stage renal disease
secondary to diabetes mellitus (L). (Adapted with permission from Ref.
20.)
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employed reliable estimates of glomerular filtration rate to com-
pare renal function in diabetic recipients of kidney or kidney-
pancreas allografts. El-Gebely and colleagues, using the clearance
of 99mtechnetium to estimate glomerular filtration rate, concluded
that renal function was comparable in diabetic recipients of a
kidney or a kidney and pancreas [55]. However, followup was
limited to two years following transplantation. More important,
patients in each group were selected on the basis of equivalent
number and severity of acute rejection episodes. These selection
criteria neutralize the importance of acute rejection on long-term
renal function.
Considering the many known or suspected factors influencing
long-term kidney survival in renal allograft recipients, the fact that
renal function in kidney and pancreas recipients is comparable to
that in recipients of only a kidney is probably fortuitous. Compared
to diabetics receiving kidneys alone, recipients of both organs tend
to have fewer HLA matches and more HLA mismatches with their
donors [43, 56], probably because HLA matching is given less
priority in allocating the combination of organs. Because of higher
rates of rejection, kidney-pancreas recipients often receive higher
doses of nephrotoxic immunosuppressants such as cyclosporine
[55, 56]. On the other hand, delayed graft function is much less
common in kidney-pancreas recipients [43, 56], probably because
of shorter cold ischemia times. Thus, the potential deleterious
effects of poorer HLA matching and higher rates of acute renal
rejection on long-term renal function appear to be balanced by
very low rates of delayed graft function and the presumed benefits
of euglycemia in preventing recurrent diabetic nephropathy.
Effects on glucose homeostasis
Glycemic control. The importance of glycemic control in slowing
the progression of nephropathy and other long-term complica-
tions of diabetes mellitus has been validated by the Diabetes
Control and Complications Trial [57]. After technically successful
pancreatic transplantation, patients with type-I diabetes mellitus
achieve a return to normal or near-normal fasting plasma glucose
levels, glucose tolerance tests, and levels of glycosylated hemoglo-
bin [58–62]. These patients thus become insulin independent for
indefinite periods. The range of blood sugar concentrations
observed during 24-hour metabolic profiling in pancreas or kid-
ney-pancreas recipients exceeds that of normal individuals, but
peak levels tend to decrease significantly over time [61], as do
glycosylated hemoglobin levels (Fig. 6) [62]. Long-term followup
studies indicate that insulin independence can be sustained for at
least 5 years such that 60% to 92% of kidney-pancreas recipients
exhibit glycosylated hemoglobin levels within the normal range 5
years after pancreatic transplantation [60, 61]. Moreover, revers-
ible pancreatic rejection episodes do not adversely affect long-
term glycemic control [62].
The euglycemia achieved after kidney-pancreas transplantation
reflects a complex interplay among several factors, including the
functioning mass of beta cells, hyperinsulinemia (particularly in
patients with systemic venous drainage of the pancreas), the
diabetogenic effects of immunosuppressive drugs, alterations in
counterregulatory hormones, the effect of denervation of the
allograft, and the prevailing level of renal allograft function.
Corticosteroids [63], cyclosporine [64], and tacrolimus [65] each
adversely affects glucose tolerance. Indeed, insulin resistance
induced by these drugs occasionally negates the benefit of func-
tioning beta cells and results in type-II diabetes mellitus [66]. The
gradual improvement in glycemic control observed more than one
year after transplantation [61, 62] probably reflects a reduction in
the dosage of these immunosuppressants over time.
Hyperinsulinemia. In kidney-pancreas recipients with systemic
venous drainage of the pancreatic allograft, the insulin response
to a glucose challenge is two to four times greater than that
observed in nondiabetic subjects [67]. Although hyperinsulinemia
probably results from decreased hepatic clearance of insulin
(because of systemic venous drainage), the rise in insulin levels
also might reflect drug-induced insulin resistance or reduced
insulin clearance in patients with impaired renal allograft func-
tion. In addition, denervation of the pancreatic allograft can lead
to incomplete suppression of insulin secretion in response to
elevated circulating insulin levels [68].
Despite circumstantial evidence to the contrary in animals [69]
and in patients with type-II diabetes mellitus [70], no evidence has
proved that hyperinsulinemia contributes to cardiovascular mor-
bidity after kidney-pancreas transplantation. A cause-and-effect
relationship is possible, however. Portal venous drainage might
alleviate hyperinsulinemia, but the procedure can be technically
difficult, and its routine use in kidney-pancreas transplantation
might increase surgical morbidity. Furthermore, in a dog model,
portal venous drainage did not entirely eliminate hyperinsulin-
emia [71]. The benefits and risks of portal pancreatic venous
drainage clearly warrant further study.
Counterregulatory mechanisms. Conventional treatment of dia-
betes mellitus with exogenous insulin frequently is complicated by
hypoglycemia, which accounts for as many as 4% of deaths in
patients with insulin-dependent diabetes mellitus [72, 73]. More-
over, intensive treatment regimens increase the frequency of
severe hypoglycemic episodes two- to fourfold compared to
conventional therapy [72]. Patients with type-I diabetes mellitus
commonly have deranged counterregulatory responses to hypo-
glycemia, including defective glucagon and epinephrine re-
sponses, that can increase the intensity and risk of hypoglycemic
episodes [74, 75]. An important feature of counterregulation is the
reversal of insulin-induced suppression of hepatic glucose produc-
tion. When insulin is infused into healthy subjects, it rapidly
suppresses hepatic glucose production, thereby reducing the
Fig. 6. Glycosylated hemoglobin values before and approximately 1 and
2 years following pancreatic transplantation. (Reprinted with permission
from Ref. 61.)
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plasma glucose level [76]. However, mobilization of hepatic
glycogen and de-novo synthesis of glucose usually prompt a rapid
rebound in hepatic glucose production. The latter response is
impaired in diabetics and can be explained by derangements in the
secretion of glucagon and epinephrine [77].
Metabolic studies have produced conflicting data regarding the
integrity of counterregulatory mechanisms after kidney-pancreas
transplantation. Diem et al demonstrated significant improve-
ment, but not normalization, of glucose recovery following insu-
lin-induced hypoglycemia in pancreas transplant recipients when
compared to diabetic nonrecipients and normal controls [78].
Improvement was largely related to a marked increase in basal
and stimulated glucagon levels, an increase that could be related
to systemic venous drainage of the pancreas and elimination of
first-pass hepatic metabolism of glucagon. On the other hand,
Battezzati et al demonstrated prolonged suppression of hepatic
glucose production and a blunted glucagon response to insulin-
induced hypoglycemia in kidney-pancreas recipients, which was
comparable to that observed in a uremic diabetic control group
[79]. The clinical implications of these observations remain un-
clear. We have observed frank hypoglycemia in occasional kidney-
pancreas recipients, most commonly among those in whom ste-
roid therapy has been withdrawn (unpublished observations). In
these cases, hypoglycemia rarely has been associated with severe
symptoms and generally is self-limited; this finding suggests that
counterregulation is sufficient to prevent severe manifestations of
hypoglycemia.
Effects on diabetic complications
In the absence of a randomized controlled trial comparing
kidney-pancreas transplantation to kidney transplantation alone
or to dialytic therapy, demonstrating the efficacy of pancreatic
transplantation in the prevention or resolution of secondary
diabetic complications has proved difficult. The popular decision
to perform combined kidney-pancreas transplants in patients with
advanced nephropathy (often coexistent with other secondary
complications) ironically might account for difficulties in demon-
strating a benefit of pancreatic transplantation. Conversely, few
transplant centers have been willing to expose diabetic patients to
the risks of life-long immunosuppression for a pancreas transplant
in the absence of the need for a concomitant kidney transplant.
The influence of pancreatic transplantation on the complications
of diabetes mellitus needs much further investigation.
Diabetic nephropathy. Histologic signs of diabetic nephropathy
can be seen in normal kidneys transplanted into diabetic patients
as early as two years after transplantation [80]. Bilous and
coworkers, who performed renal allograft biopsies on patients
who received a pancreatic transplant after prior renal transplan-
tation, reported that the mesangial expansion and increased
mesangial volume seen in diabetic patients after renal transplan-
tation alone was prevented [81]. Similarly, Wilczek et al have
shown that a pancreatic allograft prevents the development of
recurrent diabetic nephropathy in a simultaneously transplanted
kidney [82]. Although these studies suggest that a well-functioning
pancreatic transplant can prevent recurrent diabetic nephropathy
in a transplanted kidney, we have little evidence that euglycemia
achieved after pancreatic transplantation can reverse established
lesions of diabetic nephropathy in native kidneys. Fioretto et al
found that, in nonuremic patients with insulin-dependent diabetes
mellitus, mesangial expansion progressed after pancreatic trans-
plantation and was no different than that observed in persistently
hyperglycemic control patients who did not undergo transplanta-
tion [83]. Pancreatic transplantation in nonuremic patients also
requires exposure to nephrotoxic immunosuppressants, such as
cyclosporine or tacrolimus, which can accelerate progression of
the underlying diabetic nephropathy.
Retinopathy. Ramsay et al compared the eyes of 22 pancreas
recipients followed for more than one year after transplantation
with the eyes of 16 patients with failed pancreatic transplants [84].
No significant differences appeared in the groups after 24 months;
a trend toward improvement after 36 months was not statistically
significant. Although this important study suggested that pancre-
atic transplantation neither reverses nor prevents the progression
of diabetic nephropathy, it is clear that longer followup in a larger
cohort of patients is required to verify or refute that conclusion.
Neuropathy. Kennedy et al measured nerve conduction, evoked
potentials, and Valsalva ratios in 61 patients before and after
pancreatic transplantation and compared these parameters in
nonuremic diabetics who were awaiting or who had failed a
pancreatic transplant. These authors reported statistically signifi-
cant improvements in the patients with successful pancreatic
transplants [85]. Hathaway and colleagues have suggested that
pancreatic transplantation improves autonomic neuropathy, as
evidenced by improvements in Valsalva ratios [86] and in gastric
emptying [87].
Accelerated vascular disease. Whether a pancreatic transplant
can prevent the progression of arterial occlusive disease remains
to be determined. However, recent studies have documented
improvement in diabetic microangiopathy after pancreatic trans-
plantation. Abendroth et al reported a significant increase in
transcutaneous oxygen tension in kidney-pancreas recipients
when compared to that in diabetic patients receiving a kidney
transplant alone [88]. Cheung and colleagues demonstrated in-
creases in capillary size and density following successful pancre-
atic transplantation [89].
Difficulties in demonstrating a benefit of pancreatic transplan-
tation in retarding the progression of microvascular or macrovas-
cular complications of diabetes mellitus likely are related to
persistent elevations of advanced glycation end products despite
“correction” of diabetes and renal failure after kidney-pancreas
transplantation [90]. Our group has tracked the tissue and plasma
concentrations of the pentose-derived glycation end product
pentosidine after kidney or kidney-pancreas transplantation in
patients with diabetes mellitus. Pentosidine levels are elevated in
diabetic patients with normal renal function and in diabetic as well
as nondiabetic patients with end-stage renal disease [91, 92]. The
combination of diabetes mellitus and renal failure raises the
pentosidine content of plasma and tissue to a level higher than
that observed in either condition alone [91].
It is not clear whether pentosidine accumulates during renal
failure because of its underexcretion or overproduction. Never-
theless, the patient with diabetes mellitus can develop an over-
whelming burden of advanced glycation end products after kidney
failure ensues. We have shown that both renal and kidney-
pancreas transplantation are accompanied by a dramatic, but
incomplete, reduction of plasma pentosidine concentrations
within three months [93]. By contrast, levels in skin collagen are
unchanged or increased as long as 80 months after transplantation
(Fig. 7) [94]. Thus formation of advanced glycation end products
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can continue despite otherwise successful kidney or kidney-
pancreas transplantation. We and others have shown that plasma
levels of advanced glycation end products correlate inversely with
glomerular filtration rate [94, 95]. Impaired renal allograft func-
tion thus theoretically can negate the benefit of functioning beta
cells after kidney-pancreas transplantation.
Quality of life. Patients with successful pancreas transplants
usually report an improvement in quality of life [96–98]. Gross
and Zehrer polled 65 patients with functioning pancreatic allo-
grafts and compared responses with those from 66 patients whose
grafts had failed. A higher percentage of patients with functioning
allografts reported greater overall satisfaction with life (68%
versus 48%; P , 0.01), a sense of better health since transplan-
tation (89% versus 25%; P , 0.001), and the renewed ability to
care for themselves and perform their routine daily activities
(78% versus 56%; P , 0.001) [97]. In our experience, almost 90%
of kidney-pancreas recipients have been able to return to work or
school [12].
In summary, pancreatic transplantation is being performed with
increasing frequency worldwide. In theory, the benefits of eugly-
cemia achieved after a technically successful pancreas transplan-
tation would be best appreciated if the procedure were performed
in patients without renal impairment; however, combined kidney-
pancreas transplantation is performed much more commonly in
patients with end-stage diabetic nephropathy because physicians
are reluctant to use potent immunosuppressive drugs in diabetic
patients before they need a concomitant renal transplant. Kidney-
pancreas transplantation is clearly associated with rates of surgical
morbidity that exceed those observed after kidney transplantation
alone. Proven benefits of kidney-pancreas transplantation include
insulin independence and an improved quality of life. Because
kidney-pancreas transplantation usually is reserved for patients
with advanced secondary complications of diabetes, it has been
more difficult to prove that this operation arrests long-term
diabetic complications. The future of pancreatic beta-cell trans-
plantation resides in its application to diabetic patients before
they develop secondary complications. This goal likely will require
the development of safe immunosuppressant agents that do not
promote glucose intolerance or other risk factors for cardiovas-
cular disease, now the leading cause of death and graft loss after
kidney-pancreas transplantation.
QUESTIONS AND ANSWERS
DR. JOHN T. HARRINGTON (Dean, Tufts University School of
Medicine, Boston, Massachusetts): Don, it’s great to have you back
here. Thanks for a superb review. Let me begin by asking about
the current status of islet cell transplantation.
DR. HRICIK: Several factors continue to limit the success of islet
cell transplantation. Dispersed islet cells are far more immuno-
genic than islet cells transplanted as part of a vascularized
allograft. In addition, a critical number of islets are required to
assure independence from insulin. It has proved to be difficult in
practice to obtain this number from single donors. Currently, the
use of multiple human donors to harvest islets would limit the
supply of whole organs. Xenotransplantation of islets is a logical
alternative that has not yet been perfected. Hyperglycemia per se
is toxic to the islet cells. Even if an adequate number of islets are
transplanted, persistent hyperglycemia can lead to a vicious cycle
in which the available islets fail as a result of “metabolic exhaus-
tion.” Despite these limitations, several centers remain interested
in islet cell transplantation, and a small but increasing number of
patients have maintained long-term insulin independence after
islet cell transplantation using currently available technology and
immunosuppresive drugs. Most transplant physicians and sur-
geons would readily welcome successful islet cell transplantation
as an alternative to whole-organ transplantation.
DR. NICOLAOS E. MADIAS (Chief, Division of Nephrology, New
England Medical Center, Boston, Massachusetts): I have two ques-
tions. First, you mentioned that several studies have shown
improved quality of life in recipients of combined kidney-pancreas
transplants. Indeed, it must be a remarkable change to develop
independence from insulin for people who for most of their lives
had been dependent on the daily insulin injection. On the other
hand, you mentioned that there has been significant morbidity in
these patients with combined organ transplantation. Has there
been any rigorous analysis of mortality and morbidity in compa-
rable patients who received either a kidney or kidney-pancreas
transplant?
DR. HRICIK: To the best of my knowledge, a randomized trial
has never been performed to allow such rigorous comparisons.
Thus, most studies comparing outcomes of kidney and kidney-
pancreas transplant recipients are biased by the tendency to select
healthier diabetic patients for the combined procedure. Most
centers, including our own, exclude patients from kidney-pancreas
transplantation if they are over the age of 50 or if they have
significant cardiovascular disease.
DR. MADIAS: My second question relates to the so-called
protective effect of the kidney on pancreas rejection. Are there
any animal studies or studies of human pancreatic biopsies that
have examined the expression of immunomodulating molecules in
pancreatic tissue in the settings of pancreas alone versus pancreas-
kidney transplant? Also, could you comment more on the discrep-
ancy in acute allograft rejection between animal and human
kidney-pancreas transplantation?
DR. HRICIK: It is possible that humans differ from animals in
terms of the differential expression of major histocompatibility
Fig. 7. Comparison of plasma protein and skin collagen pentosidine
content before (solid bars) and after (shaded bars) kidney or kidney-
pancreas transplantation; *P 5 0.02. (Reprinted with permission from
Ref. 93.)
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antigens and other immunomodulating molecules after a kidney-
pancreas transplant, but I am not aware of studies investigating
this possibility. The discrepant rates of acute allograft rejection
noted in human versus animal studies could reflect the bias of
physicians to more aggressively diagnose and treat acute rejection
in kidney-pancreas transplant recipients. On the other hand, it is
hard to ignore the fact that virtually all centers have found higher
rates of acute rejection in these patients.
DR. ANDREW J. KING (Division of Nephrology, New England
Medical Center): In my limited experience with patients who have
had a pancreas transplant, it can be difficult to maintain their
plasma bicarbonate in a reasonable range. Could you give us some
insight into your approach to this problem? The chronic acidosis
these patients suffer might contribute to malnutrition by altering
muscle metabolism, as well as lead to metabolic bone disease.
Have you encountered these chronic complications in your long-
term pancreas recipients?
DR. HRICIK: The metabolic acidosis sustained in patients who
are recipients of bladder-drained pancreatic allografts can be
profound and difficult to treat. Studying the impact of the acidosis
on bones in these patients is quite difficult because of the
compounding effects of underlying renal osteodystrophy and of
immunosuppressive therapy. Moreover, in our experience, pan-
creatic bicarbonate wasting appears to subside with time in the
majority of patients, suggesting that the exocrine function of the
pancreatic allograft somehow involutes even when the organ’s
endocrine function remains intact.
DR. KING: My second question relates to the strategies for
immunosuppression in pancreas transplantation. In view of the
high rates of rejection reported in these patients, has immuno-
suppression been modified for pancreas or kidney-pancreas recip-
ients?
DR. HRICIK: In most transplant centers, kidney-pancreas recip-
ients are treated more aggressively than are kidney-alone recipi-
ents. For example, we continue to use polyclonal antibodies for
induction therapy in all kidney-pancreas recipients but now avoid
antibody induction in kidney transplant recipients who exhibit
good immediate renal allograft function. Some centers have
reported excellent results and lower acute rejection rates in
kidney-pancreas transplantation using tacrolimus as a substitute
for cyclosporine [99]. Interestingly, overt hyperglycemia has not
been a problem in this early experience despite the well-known
diabetogenic effects of tacrolimus.
DR. RONALD D. PERRONE (Division of Nephrology, New England
Medical Center): Could you comment in more detail about the
reversibility of diabetic complications? Is there a threshold at
which one might assume that the complications are irreversible?
Has enough experience accumulated that allows us to make any
judgments about that?
DR. HRICIK: It could be argued that pancreas transplantation
should be performed long before the development of diabetic
complications. However, few transplant physicians are willing to
subject diabetic patients to the side effects of immunosuppression
unless it is deemed necessary for a concomitant kidney transplant.
In the absence of adequate data to determine whether diabetic
complications can be reversed by pancreas transplantation, I think
it would be premature to establish arbitrary clinical thresholds
beyond which the procedure would be avoided.
DR. AJAY SINGH (Division of Nephrology, New England Medical
Center): You indicated that the kidney and pancreas are not
equally vulnerable to acute rejection. Is the same true for chronic
rejection?
DR. HRICIK: Our experience differs from that of Walker et al
[36], who recently described their experience with late pancreatic
allograft rejection episodes (occurring more than 12 months after
transplantation). In our experience, late loss of a pancreatic
allograft is rare, occurring in less than 3% of patients. It is now
recognized that immunologic as well as nonimmunologic factors
contribute to chronic allograft dysfunction. The observation that
chronic renal rejection can occur in the absence of chronic
pancreas rejection in a patient who has received both allografts
from the same donor tends to suggest that nonimmunologic
factors are more important than immunologic factors in the
clinical expression of chronic renal allograft rejection.
DR. HARRINGTON: I assume that the gross histologic findings of
acute rejection of the pancreas and the kidney are similar. Are
there any differences in the kinds of cells that might preferentially
attack the pancreas or kidney, or are they the same?
DR. HRICIK: The sequential histopathologic changes of acute
rejection in the pancreas have been best studied in animal models
[100]. To my knowledge, cellular subtypes are no different than
those observed in renal allograft rejection.
DR. ANDREW S. LEVEY (Division of Nephrology, New England
Medical Center): Thank you for summarizing the data, limitations,
and intepretation of these uncontrolled studies. Would you agree
with the conclusion that combined kidney-pancreas transplanta-
tion is an expensive and morbid procedure that appears to affect
primarily the quality of life? Our current practice selects people
who may derive the least benefit from persistent euglycemia. If we
expanded the recipient pool to include all type-I diabetics with
renal failure, and even all type-I diabetics with renal disease, we
would surely face a shortage of pancreases. Is this approach going
to remain a niche therapy applicable to only the few people who
receive combined kidney-pancreas transplants? Or are we perfect-
ing surgical and immunosuppressive techniques so we can even-
tually apply them to the larger population of type-I diabetics?
DR. HRICIK: Improvements in surgical techniques or immuno-
suppressive therapy will have little impact on the shortage of
cadaver donors. This shortage remains the most important reason
why kidney-pancreas transplantation can be offered to only a
limited number of patients with diabetes. If safer immunosuppres-
sive drugs were available, pancreas transplantation might be
offered to patients earlier in the course of their disease, but this
would only magnify the donor shortage by increasing the pool of
candidates.
DR. MADIAS: It is somewhat surprising that renal function in
kidney-pancreas transplant recipients is not different than that in
control groups despite a high incidence of acute rejection. Have
long-term followup studies been performed to verify that this is
the case beyond two post-transplant years?
DR. HRICIK: We have recently compared long-term renal func-
tion, estimated by the slopes of 1/Cr versus time, in kidney and
kidney-pancreas transplant recipients followed for as long as 5
years [101]. A statistically insignificant trend toward more rapid
deterioration of renal function in the kidney-pancreas group
suggested that the negative effects of acute rejection outweigh the
benefits of the concomitant pancreas transplant over long periods.
In this analysis, early acute rejection episodes, defined as occur-
ring within the first 3 months after transplantation, had little
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impact on long-term renal function compared to later rejection
episodes.
DR. MARK E. WILLIAMS (Director of Dialysis, Beth Israel-Dea-
coness Medical Center West, Joslin Diabetes Center, Boston): I have
two questions. First, let me move from abstract philosophy to
pragmatic philosophy. For more and more patients with renal
failure, living donors are the solution to prolonged waiting for
cadaver organs. How do you counsel diabetics with renal failure
who have available living kidney donors with regard to pancreas
transplantation?
DR. HRICIK: I strongly advise them to consider a living-donor
kidney transplant as the first option for at least three reasons.
First, the long-term success of kidney transplantation is clearly
superior after living-donor transplantation. Second, with currently
available immunosuppression, more centers are willing to offer a
pancreas-alone transplant from a cadaver donor following a
live-donor kidney transplant. Finally, our experience tracking
AGE levels after transplantation suggests that the reduced burden
of AGEs after kidney-pancreas transplantation derives predomi-
nantly from normalizing glomerular filtration rate.
DR. WILLIAMS: I think it’s important that you highlight the
ongoing problem of cardiovascular disease in these recipients.
Our own data suggest that peripheral vascular disease leading to
amputation, which your patient experienced, is accelerated. Have
you evaluated specific risk factors? Hyperlipidemia would be one
aggravated by both the drugs and hyperinsulinemia. What is your
specific clinical approach in these patients? Specifically, how
attentive are you to the pretransplant evaluation of peripheral
vascular disease, and how do you monitor patients post transplan-
tation?
DR. HRICIK: All our patients are evaluated noninvasively with
Doppler scanning of the ileac vessels to determine their suitability
for the required vascular anastomosis. Although some centers
have reported improvement in microangiopathy after pancreas
transplantation [88, 89], I am unaware of studies that have
compared macrovascular complications in kidney versus kidney-
pancreas recipients.
DR. MADIAS: Is recurrent autoimmune diabetes an issue for the
patient with a grafted pancreas, or is the immunosuppressive
regimen fully protective?
DR. HRICIK: The immune autoreactivity against beta cells in
patients with type-I diabetes is life-long. Unless immunosuppres-
sion is employed, the disease will recur in a pancreatic allograft
[102]. However, it is generally believed that the level of immuno-
suppression required to prevent allograft rejection far exceeds
that required to prevent recurrence, so this is not a practical issue.
DR. MADIAS: You mentioned an increasing tendency of sur-
geons to perform enteric drainage of the pancreas. Has the issue
of surgical technique, that is, bladder versus enteric drainage,
been examined prospectively regarding patient and graft survival?
DR. HRICIK: There has never been a randomized trial, but the
International Pancreas Transplant Registry recently reported data
covering a 2-year span from 1994 to 1996 [103]. During that time,
the rate at which enteric drainage has been performed has
increased from 2% to 27%. However, there were no statistically
significant differences in graft or patient survival.
DR. MADIAS: I found the data on pentosidine very interesting.
Could you address the discrepancy between your data and those
of Dr. Vlassara’s group showing rapid normalization of serum
AGE levels after kidney transplantation?
DR. HRICIK: The discrepant results might be related to differ-
ences in the assays employed to measure AGEs. The antibodies
used in the ELISA that Vlassara and her colleagues have em-
ployed recognize AGEs bound to peptides of various sizes. Small
peptides with molecular weights of 1000 kD to 3000 kD are
normally filtered by the kidney, can be retained in patients with
renal failure, and return to normal when renal failure is corrected
after transplantation. Pentosidine is a small molecule that modi-
fies proteins of all sizes. It is measured chemically (by HPLC)
after complete hydrolysis of peptides and proteins. Although
plasma pentosidine levels closely correlate with estimates of
glomerular filtration rate, it seems intuitively unlikely that the
decrease in plasma levels after renal transplantation could result
from the sudden filtration of macromolecules. It is more likely
that the correlation between AGE levels and renal function
reflects overproduction of these compounds in renal failure and
not underexcretion.
Reprint requests to Dr. D.E. Hricik, Department of Medicine, University
Hospitals of Cleveland, 11100 Euclid Avenue, Cleveland, Ohio 44106, USA
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